Dr. Sangro on the Efficacy of Nivolumab in HCC

Bruno Sangro, MD, PhD
Published: Tuesday, Jun 27, 2017



Bruno Sangro, MD, PhD head of Hepatology Unit, Internal Medicine Department, Clínica Universidad de Navarra, discusses the efficacy of nivolumab (Opdivo) in patients with hepatocellular carcinoma (HCC).

Usually in phase Ib/II trials, efficacy is not observed. However, in this trial investigating nivolumab, there was clinically relevant anti-tumor activity, explains Sangro.

According to Sangro, the response rate was between 15% to 20%, the median duration of response was 17 months, and a portion of patients had prolonged stable disease.



Bruno Sangro, MD, PhD head of Hepatology Unit, Internal Medicine Department, Clínica Universidad de Navarra, discusses the efficacy of nivolumab (Opdivo) in patients with hepatocellular carcinoma (HCC).

Usually in phase Ib/II trials, efficacy is not observed. However, in this trial investigating nivolumab, there was clinically relevant anti-tumor activity, explains Sangro.

According to Sangro, the response rate was between 15% to 20%, the median duration of response was 17 months, and a portion of patients had prolonged stable disease.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x